Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?

Kocaturk E., BÜLBÜL BAŞKAN E., SU KÜÇÜK Ö., Ozdemir M., Ornek S., Can P. K., ...More

ANAIS BRASILEIROS DE DERMATOLOGIA, vol.97, no.5, pp.592-600, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 97 Issue: 5
  • Publication Date: 2022
  • Doi Number: 10.1016/j.abd.2022.03.003
  • Journal Name: ANAIS BRASILEIROS DE DERMATOLOGIA
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, Directory of Open Access Journals
  • Page Numbers: pp.592-600
  • Keywords: Biomarker, Chronic urticaria, Cyclosporine, Omalizumab, BIOMARKERS
  • Hacettepe University Affiliated: Yes

Abstract

Background: Chronic Spontaneous Urticaria (CSU) is characterized by recurrent wheals and/or angioedema for longer than 6-weeks. Guidelines recommend Omalizumab (Oma) as first-line and Cyclosporine-A (Cs-A) as second-line treatment in antihistamine resistant CSU. This step-wise algorithm might be time-consuming and costly.